MedTrace Logo

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

NCT06387056 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-04-26

No results posted yet for this study

Summary

To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

Conditions

Interventions

DRUG

Rezvilutamide

240mg by mouth once a day for 24 weeks.

DRUG

Goserelin Microspheres for Injection

3.6mg by intramuscular injection once 4 weeks for 24 weeks.

DRUG

Docetaxel

70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

DRUG

Pamiparib

60mg by mouth twice a day for 20 weeks.

DRUG

Cisplatin

70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

DRUG

Tislelizumab

200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Kaiyan Zhang, M.D. · The First Affiliated Hospital of Xiamen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-04-01
Completion
2029-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06387056 on ClinicalTrials.gov